3 April 2009

Recent Investments

Takeda Pharmaceutical Company Limited and its wholly-owned UK-based subsidiary for overseeing pan-European sales & marketing, Takeda Pharmaceutical Europe Limited jointly announced the start of its own sales and marketing operations in Spain.

In Spain, the fifth largest pharmaceutical market in Europe, Takeda Farmacéutica España S.A., a wholly-owned subsidiary of Takeda, will start promotional activities for Blopress® and Glustin® .

"We are pleased with the expansion of geographical coverage in Spain, one of the most important markets in Europe, and also the nationwide coverage in the Republic of Ireland" said Erich Brunn, CEO of TPEU. "We will actively introduce products from our portfolio into these two countries, so that theywill help many more patients suffering from a variety of diseases". "The commencement of our own sales and marketing operations in Spain and the Republic of Ireland is contributing to one of our key management initiatives, namely the enhancement of our presence in each region of the world to further establish Takeda as a world-class pharmaceutical company", said Yasuchika Hasegawa, President of Takeda.

Takeda now has its own sales and marketing operations in eight European countries: in addition to Spain and Ireland, there are wholly-owned subsidiaries in France, UK, Italy, Germany, Austria and Switzerland.

Source: http://www.drugs.com/news.html, March 30, 2009